In summary, there was no evidence of GVHD flare with LD IL-2 treatment, and 12 of 23 patients with GVHD showed partial response during the 8-week treatment period, with lower risk for erythema, higher joint mobility and gait, and improvement of liver function. This evidence concerns the gene IL2 and graft versus host disease.